Syntheses and functional studies of self-adjuvanting anti-HER2 cancer vaccines.

Syntheses and functional studies of self-adjuvanting anti-HER2 cancer vaccines.
Chem Asian J. 2019 Oct 07;:
Authors: Feng Q, Manabe Y, Kabayama K, Aiga T, Miyamoto A, Ohshima S, Kametani Y, Fukase K
Abstract
A 9-mer peptide MFCH401 (N: 165-173: DTILWKDIF), which is located in the extracellular domain of HER2, has been predicted to be a novel epitope. Self-adjuvanting anti-HER2 vaccine constructs were designed and synthesized via covalently attached MFCH401 or its linear tandem repeats (2×MFCH401, 3×MFCH401) to a lipopeptide Pam3CSK4 via iterative condensation reaction. The in vivo results showed the Pam3CSK4-MFCH401 vaccine construct can induce higher antibody titers of IgG and IgM than that of other conjugates, and the analysis of changes in plasma cytokines level indicating the activation of Th1 cells and NK cells. In addition, Pam3CSK4-MFCH401 vaccine conjugate induced a specific immune response to HER2-overexpressing human BT474 cell. Our data clearly indicated MFCH401 was a promising epitope, moreover, its linear tandem repeats were unsuitable for anticancer vaccine design when conjugating with Pam3CSK4, which provided useful evidence for developing further anti-HER2 cancer vaccines.
PMID: 31591824 [PubMed - as supplied by publisher]

Source: Chemistry, an Asian Journal - October 6, 2019 Category: Chemistry Authors: Feng Q, Manabe Y, Kabayama K, Aiga T, Miyamoto A, Ohshima S, Kametani Y, Fukase K Tags: Chem Asian J Source Type: research